http://www.envita.com/conditions-we-treat/cancer/immunotherapy/ - Immunotherapy for Cancer Treatment is absolutely necessary, and many are lacking it. At Envita, it is not an afterthought but in fact, our focus. The immune system is the first and last defense against cancer, and we believe to be critical for long-term success.

1. Envita's AAIT - a Powerful Immunotherapy
for Cancer
AAIT is an acronym for autologous adoptive immune therapy and describes a therapy
derived from the patient’s own blood, and is re-infused during treatment. There are
myriad strategies for immunotherapy and just as many treatments that fall under the
heading “autologous adoptive immunotherapy.” That being said – not all options are
comparable.
Enivta's immunotherapy, AAIT, involves 4 major cell types including:
• Natural killer cells
• Natural killer T cells
• Cytokine-induced killer cells
• Cytotoxic T lymphocytes
The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the
primary focus of Envita’s AAIT immunotherapy serums.
Keys to Envita's AAIT Uniqueness
1) Envita's protocol for AAIT is designed to optimize the expansion of natural killer cells -
the most potent cancer fighting component of the cellular immune system. Most immune
therapies do include natural killer cells, and those that do only expand them in low
numbers with little activation.
2) Envita's AAIT protocol takes only 4-5 weeks to grow your cells, so you can begin to
experience benefits quickly. Moreover, while other immune therapies administer just
100-200 million cells per treatment, Envita delivers roughly 100 times as many during
the course of your treatment.

2. 3) Multitudes of published studies demonstrate the effects of adoptive immune therapy
in cancer patients for which Envita has identified and improved upon the best. Company
protocol insists upon the highest-level of procedure for the expansion and application of
cells for each immunotherapy treatment.
4) Unlike other published immune therapies, Envita's AAIT is the only one that can be
used as a “stand-alone.” Moreover, it may also be administered in conjunction with other
therapies to enhance the cells’ effects in patients – an incomparable benefit. Envita's
AAIT therapy is not focused solely on expanding cells in the lab; rather, our goal also
includes keeping them active until reintroduced to the patient’s body.
5) Envita’s AAIT offers far greater tumor kill, or cytotoxicity than that of other well-
regarded cancer cell vaccines / immunotherapies found throughout the world. In brief,
this means Envita’s activated natural killer cells in AAIT deliver considerably higher
tumor obliteration.
6) In summary, the most direct manner to stack Envita’s proprietary immunotherapy
against the others, includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can kill).
Envita’s AAIT immunotherapy consistently delivers “significantly greater tumor
kill”.
b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy comes
with 100 times the cell dosage than the others.
c. Sterility (quality control measures) – Envita AAIT immunotherapy is completely
contaminant free.
If you have any questions concerning Envita's AAIT immunotherapy, please consult with
Envita's team of physicians and patient educators. This immunotherapy is offered at
Envita’s international cancer center in Mexico.